oncolyt
virotherapi
promis
form
gene
therapi
cancer
employ
natur
agent
find
destroy
malign
cell
purpos
review
provid
introduct
topic
field
research
point
current
observ
insight
idea
circul
literatur
strive
acknowledg
mani
differ
oncolyt
virus
possibl
give
broader
pictur
target
cancer
use
virus
newest
addit
panel
oncolyt
virus
includ
avian
adenoviru
foami
viru
myxoma
viru
yabalik
diseas
viru
echoviru
type
bovin
herpesviru
saimiri
viru
felin
panleukopenia
viru
sendai
viru
nonhuman
coronavirus
although
promis
virotherapi
still
face
mani
obstacl
need
address
includ
emerg
virusresist
tumor
cell
notion
virus
may
abl
erad
cancer
exist
sinc
earli
centuri
sever
virus
test
experiment
set
human
among
first
virus
use
control
fashion
clinic
studi
vaccin
strain
rabi
viru
treat
patient
melanomatosi
eight
show
tumor
regress
year
later
oncolyt
efficaci
adenoviru
serotyp
type
time
refer
ri
respiratori
infecti
viru
test
human
well
flaviviru
west
nile
viru
strain
egypt
paramyxovirus
mump
newcastl
diseas
viru
ndv
also
mani
virus
test
anim
model
instanc
bovin
enteroviru
show
effici
lysi
syngen
tumor
immunocompet
mice
moreov
mani
case
report
describ
use
sever
differ
virus
includ
one
previous
undescrib
pathogenesi
one
larger
studi
human
one
simian
adenoviru
serotyp
administ
patient
cervic
cancer
result
necrosi
transient
tumor
regress
patient
anoth
report
six
differ
virus
administ
success
patient
suffer
acut
leukemia
third
report
summar
use
differ
virus
strain
total
patient
variou
type
advanc
cancer
oncolyt
effect
observ
use
virus
studi
groundbreak
provid
first
glimps
therapeut
potenti
human
efficaci
virotherapi
unimpress
mani
virus
elicit
sideeffect
ultim
end
trial
result
initi
interest
virus
anticanc
agent
declin
follow
decad
deduc
number
public
time
studi
mainli
conduct
use
experiment
model
exampl
report
describ
test
oncolyt
potenti
differ
virus
erlich
ascit
tumor
mice
later
advent
modern
biotechnolog
concept
gene
therapi
interest
virus
treatment
cancer
rekindl
today
virotherapi
assert
formid
treatment
option
alongsid
surgeri
chemoand
radiat
therapi
mani
new
virotherapeut
candid
emerg
could
call
second
come
virus
addit
direct
tumor
target
sever
altern
strategi
cancer
gene
therapi
develop
address
briefli
review
foremost
among
tumor
vaccin
cancer
immunotherapi
aim
evok
tumorspecif
immun
capabl
erad
establish
tumor
well
maintain
immunolog
memori
tumorspecif
immun
may
stimul
eg
product
tumor
associ
antigen
taa
either
within
tumor
cell
cell
via
opson
tumor
cell
antibodi
produc
viral
vector
anoth
approach
involv
enhanc
tumor
cell
recognit
cell
dendrit
cell
transduc
virus
encod
immunostimulatori
cytokin
mani
virus
evok
strong
immun
respons
may
thu
function
adjuv
henc
oncolysi
consid
twoprong
strategi
cancer
cell
destroy
one
hand
direct
action
viral
replic
becom
target
recognit
immun
system
idea
spur
develop
call
oncolys
use
sever
human
trial
vaccin
cancer
one
promis
studi
led
dr
william
cassel
treat
patient
stage
iii
malign
melanoma
ndvoncolys
oncolys
prepar
ex
vivo
use
either
exist
isol
melanoma
cell
line
patient
treat
inject
subcutan
thigh
forearm
patient
treatment
regimen
gradual
increas
weekli
inject
month
interv
year
continu
therapi
treat
patient
tumorfre
year
remain
tumorfre
follow
year
total
surviv
see
chapter
ref
nine
patient
die
year
followup
tumorfre
die
caus
trial
limit
includ
histor
control
encourag
warrant
studi
larger
scale
comparison
although
surviv
highli
depend
substag
diseas
primarili
determin
number
region
lymph
node
involv
overal
surviv
stage
iii
melanoma
report
fact
despit
aggress
chemoand
radiat
therapi
overal
surviv
rate
common
form
metastas
cancer
improv
past
decad
cast
doubt
true
use
convent
form
treatment
emphas
need
altern
therapi
oncolys
also
use
later
clinic
trial
degre
success
result
ambigu
even
use
viru
chapter
ref
still
measur
overal
surviv
viral
oncolys
proven
better
convent
therapi
possibl
detriment
effect
chemoand
radiat
therapi
immun
system
discuss
chapter
ref
relationship
virus
cancer
immun
system
complex
may
reveal
surpris
aspect
exampl
grow
amount
evid
show
vaccin
common
human
pathogen
influenza
vaccinia
tuberculosi
reduc
risk
develop
melanoma
later
life
molecular
basi
phenomenon
still
unknown
crossprotect
viral
epitop
cancer
propos
play
role
type
cancer
particular
viru
etiolog
agent
eg
papillomaviru
cervic
cancer
hepat
b
viru
hepatocellular
carcinoma
vaccin
virus
proven
highli
prophylact
rare
therapeut
establish
cancer
moreov
control
clinic
laboratori
experi
asid
hundr
case
spontan
remiss
document
sinc
begin
centuri
although
underli
mechan
remiss
remain
unclear
mani
case
remiss
phase
preced
fever
spur
notion
fever
therapi
cancer
like
immun
system
play
signific
role
clear
tumor
mass
possibl
augment
common
infect
elev
bodi
temperatur
may
also
benefici
virotherapi
instanc
normal
cell
becom
refractori
adenovirus
cultur
high
temperatur
wherea
cancer
cell
may
display
even
enhanc
permiss
far
oncolyt
bacteria
concern
least
attenu
salmonella
typhimurium
clostridium
novyi
use
clinic
trial
target
variou
type
cancer
see
wwwwileycoukgenmedclin
wwwclinicaltrialsgovct
final
also
tumor
vasculatur
constitut
ampl
target
viral
transduct
goal
achiev
transduct
endotheli
cell
blood
vessel
solid
tumor
order
produc
oncotox
prodrug
prevent
tumor
spread
restrict
angiogenesi
come
chapter
discuss
possibl
mechan
viral
oncolysi
summar
problem
virotherapi
current
face
cancer
cell
gener
host
virus
prefer
type
cell
mani
genet
physiolog
featur
specif
malign
cell
relat
particular
gainoffunct
lossoffunct
mutat
explain
phenomenon
cancer
cell
undergon
minievolut
involv
extens
pointmut
well
larger
chromosom
shift
alter
term
chromosom
instabl
provid
select
growth
advantag
normal
cell
howev
cancer
cell
may
gain
mani
growthenhanc
attribut
may
simultan
lose
critic
compon
intracellular
defens
mechan
thu
becom
fertil
ground
replic
mani
virus
instanc
although
mani
cancer
cell
type
resist
apoptosi
due
activ
ra
gainoffunct
reoviru
replic
better
cell
function
doublestrand
rnaactiv
protein
kinas
r
pkr
inhibit
activ
ra
subsequ
inhibit
pkr
also
thought
underli
permiss
tumor
cell
oncolyt
herp
simplex
virus
hsv
delet
main
neurovirul
gene
normal
protein
overcom
restrict
replic
pose
function
pkr
recent
report
shown
even
vector
delet
replic
cancer
cell
pkr
function
case
defect
pi
pathway
allow
hsv
genom
translat
malign
cell
may
express
higher
level
viru
receptor
compar
normal
cell
gainoffunct
make
suscept
infect
instanc
mani
type
cancer
cell
overexpress
daf
receptor
coxsackieviru
anoth
enteroviru
echoviru
type
gain
preferenti
entri
ovarian
cancer
cell
due
overexpress
domain
integrin
b
polioviru
infect
cell
express
receptor
abund
mani
human
cancer
cell
type
alphaviru
sindbi
viru
gain
preferenti
access
tumor
cell
result
overexpress
kda
laminin
receptor
howev
virus
util
receptor
abund
also
normal
cell
mechan
govern
preferenti
replic
cancer
cell
probabl
intracellular
instanc
despit
ndv
mump
viru
use
sialic
acid
receptor
alphavirus
use
heparan
sulphat
abundantli
express
also
mani
normal
cell
virus
show
high
cancer
cell
select
case
prefer
cancer
cell
stem
fact
mani
tumor
cell
display
impair
antivir
respons
due
failur
critic
compon
interferon
ifn
respons
system
lossoffunct
fact
one
strategi
enhanc
tumor
cell
specif
oncolyt
virus
mutat
induc
potent
ifn
respons
reduc
replic
virus
normal
cell
cancer
cell
remain
permiss
virus
unabl
respond
ifn
signal
also
sever
cell
typespecif
promot
avail
target
virus
tumor
cell
promot
activ
altern
cancer
cell
may
overexpress
certain
gene
make
suscept
viral
deliv
prodrug
growth
inhibitor
instanc
squamou
carcinoma
cell
overexpress
survivin
make
possibl
use
therapi
specif
target
gene
hand
mani
virus
molecular
basi
preferenti
infect
cancer
cell
less
clear
virus
may
even
display
anticanc
effect
involv
direct
kill
cell
exampl
parvovir
protein
interfer
mani
cellular
process
induc
apoptosi
particularli
transform
cell
parvovirus
may
exhibit
oncosuppress
activ
addit
oncolysi
prevent
cellular
transform
tumorigenesi
even
perplex
preinfect
balbc
mice
mous
parvoviru
led
enhanc
graft
reject
syngen
sarcoma
cell
despit
cell
refractori
infect
viru
anoth
studi
replicationdefect
human
cytomegaloviru
vector
abl
halt
tumor
growth
distant
metastas
mice
without
direct
infect
tumor
cell
mechan
remain
larg
unresolv
may
still
use
cancer
therapi
futur
final
virus
engin
cancer
cell
specif
exampl
adenovir
vector
delet
gene
order
restrict
replic
cell
function
protein
impair
includ
mani
type
cancer
cell
wherea
protein
wildtyp
wt
adenoviru
prevent
induc
apoptosi
respons
infect
vector
replic
product
cell
lack
function
requir
absolut
howev
seem
influenc
factor
includ
cell
type
anoth
exampl
herp
virus
lose
abil
infect
nondivid
cell
delet
thymidin
kinas
gene
therebi
forc
virus
prefer
tumor
cell
normal
cell
virus
mutat
depend
certain
molecular
defect
cancer
cell
call
condit
replic
ie
restrict
replic
permiss
cell
follow
chapter
introduc
type
viral
vector
use
cancer
target
frequent
literatur
term
amplicon
capsidreplac
vector
gutless
vector
pseudovirion
replicon
singlecycl
vector
viru
base
nanoparticl
virallik
particl
vlp
virosom
appear
delv
world
viral
vector
gene
therapi
term
attribut
vector
manner
habitu
particular
subfield
research
origin
impli
construct
unabl
spread
cell
cell
mean
autonom
replic
word
although
replic
viral
genom
may
occur
vector
produc
progeni
virion
henc
descript
term
replicationdefici
replicationdefect
distinct
made
replicationdefici
vector
contain
gene
necessari
replic
viral
particl
eg
replicon
capsidreplac
vector
construct
express
viral
gene
eg
amplicon
viru
base
nanoparticl
vlp
gutless
vector
pseudovirion
howev
discrep
use
term
exampl
use
term
vlp
describ
replicon
other
use
particl
complet
devoid
viral
genom
inabl
replicationdefect
virus
spread
caus
delet
region
viral
genom
code
structur
protein
mutat
abrog
product
viral
capsid
andor
envelop
protein
thu
elimin
possibl
risk
spread
infect
except
rule
exist
howev
replicationdefici
vector
express
fusogen
membran
glycoprotein
fmg
may
allow
vector
spread
neighbor
cell
absenc
extracellular
step
involv
viru
particl
system
truncat
viral
genom
passiv
transfer
new
cell
via
format
multinucl
syncytia
cell
fuse
togeth
seen
exampl
cell
cultur
infect
member
paramyxovirida
famili
addit
facilit
viru
spread
syncytiosom
format
may
directli
toxic
cell
syncytia
also
readili
recogn
immun
system
increas
tumorkil
capac
oncolyt
virus
even
confer
kill
capac
otherwis
apathogen
construct
viral
genom
may
also
piggyback
exocytos
vesicl
jump
cell
cell
tight
junction
document
varieti
differ
virus
viral
vector
moreov
vector
may
base
specif
viru
yet
still
packag
vlp
exampl
call
plasmovirus
plasmid
sole
viral
element
encapsid
signal
gene
virion
capsidenvelop
plasmovirus
shown
drive
product
foreign
insert
control
heterolog
promot
propag
infect
product
bud
vlp
whether
delet
viral
replicas
structur
gene
clone
capac
replicationdefici
construct
often
impress
howev
due
inabl
produc
progeni
becom
clear
replicationdefici
construct
lack
efficaci
compar
replicationcompet
counterpart
gener
sens
achiev
viral
induc
cell
death
either
follow
mechan
requir
viral
replic
caus
lysi
due
accumul
virion
cellular
transcriptiontransl
machineri
usurp
b
express
import
viral
protein
cytotox
influenc
cellular
function
may
lead
apoptosi
mean
virus
use
target
cancer
cell
ie
oncotrop
virus
kill
consid
oncolyt
true
oncolyt
virus
whether
replicationdefici
replicationcompet
meet
criteria
oncotrop
virus
taken
human
cell
gene
express
infect
abort
virus
includ
canin
parvoviru
baculoviru
canarypoxviru
develop
vector
cancer
target
none
display
intrins
oncolyt
capac
moreov
mani
nonlyt
virus
highli
immunogen
may
serv
adjuv
boost
antitumor
immun
respons
exampl
immunogen
virus
plant
kingdom
bacteri
phage
carri
taa
develop
tumor
vaccin
human
importantli
viru
particl
viru
famili
may
induc
cell
death
complet
absenc
replic
instanc
directli
upon
entri
uvinactiv
avian
reoviru
induc
apoptosi
sever
avian
mammalian
cell
line
although
molecular
basi
phenomenon
unknown
number
viral
particl
taken
uncoat
seem
play
crucial
role
turn
put
constraint
draw
conclus
viral
oncolyt
efficaci
high
moi
use
cell
death
case
could
also
result
high
viral
load
also
mani
viral
gene
product
potent
oncotox
agent
may
use
conjunct
viral
vector
singl
therapeut
exampl
kda
protein
apoptin
encod
gene
chicken
anemia
viru
gene
product
adenoviru
open
read
frame
cytotox
cancer
cell
normal
cell
express
apoptin
adenovir
parvovir
vector
enhanc
oncolyt
efficaci
vitro
vivo
without
increas
cytotox
toward
nontransform
cell
member
increas
number
viru
famili
consid
cancer
gene
therapi
tabl
mani
human
virus
implic
carcinogenesi
sudden
convers
oncogen
viru
oncolyt
agent
may
seem
implaus
nevertheless
despit
continu
risk
insert
mutagenesi
lead
unfortun
setback
recent
xlink
scid
gene
therapi
trial
retrovirus
exclud
develop
virotherapi
fact
signific
effort
put
make
virus
safer
recent
breakthrough
retrovir
gene
therapi
indic
perhap
somewhat
counterintuit
certain
condit
genom
integr
benefici
recent
studi
shown
alter
express
gene
human
cell
retrovir
integr
affect
cell
function
cell
growth
anoth
vehicl
extens
use
cancer
gene
therapi
vaccinia
viru
vv
express
protein
shown
circumst
oncogen
even
surpris
polyomaviru
extens
use
transform
differ
type
cell
also
recent
proven
effici
cancer
target
vector
vector
tag
protein
respons
cellular
transform
delet
although
recombin
vector
still
integr
tumorigenesi
observ
moreov
despit
epsteinbarr
viru
associ
number
differ
type
cancer
therefor
classifi
type
carcinogen
recent
develop
express
vector
nonlyt
tumor
vaccin
b
cell
lymphoma
vector
render
safe
nononcogen
replicationdefici
delet
two
oncogen
gene
one
gene
critic
lytic
cycl
viru
anoth
herp
viru
oncogen
properti
human
herp
simplex
viru
type
recent
engin
oncolyt
cancer
target
delet
ribonucleotid
reductas
gene
thu
even
oncogen
virus
may
serv
tool
cancer
target
delet
tumorigen
gene
compon
versatil
particular
viru
cancer
kill
determin
type
genom
whether
viru
envelop
rather
advantag
phenotyp
characterist
tropism
apathogen
human
chapter
introduc
oncolyt
virus
use
field
cancer
virotherapi
well
virus
display
signific
oncotrop
tabl
although
mani
virus
may
never
make
clinic
may
contribut
virotherapi
research
way
eg
function
model
provid
insight
mechan
oncolysi
extens
list
ongo
clinic
trial
see
refer
also
warmli
recommend
book
viral
therapi
human
cancer
dr
joseph
sinkov
joseph
horvath
pioneer
field
flavivirida
nodavirida
nf
enteroviru
live
echoviru
type
live
coxsackieviru
experiment
set
clinic
trial
replicon
vector
replicationcompet
vector
polioviru
type
also
clinic
trial
wwwwileycoukgenetherapyclin
live
attenu
polioviru
bovin
enteroviru
gammaretroviru
replicationdefici
replicationcompet
momlv
vector
also
use
clinic
trial
replicationdefici
vector
base
replicationcompet
vector
base
foami
viru
list
viru
famili
gener
vertebr
host
rang
accord
report
intern
committe
taxonomi
virus
wwwncbinlmnihgovictvdbictvindexhtm
viru
speci
strain
vector
current
use
show
promis
becom
tool
virotherapi
although
list
mean
absolut
provid
glimps
extent
research
field
expand
sinc
earli
day
gene
therapi
virus
use
gener
list
unless
still
use
today
importantli
list
show
inher
oncolyt
virus
oncotrop
vector
intend
direct
tumor
transduct
viral
vector
use
ex
vivo
transgenemedi
bystand
kill
tumor
vaccin
omit
nf
data
use
member
viru
famili
cancer
target
could
found
pubm
use
combin
viru
famili
speci
strain
vector
name
keyword
cancer
oncolyt
virotherapi
tumor
target
intratumor
underlin
virus
oncolyt
oncotrop
multitud
differ
virus
use
studi
erad
tumor
anim
model
develop
purpos
virotherapi
one
report
differ
virus
famili
arenavirida
bunyavirida
flavivirida
reovirida
togavirida
famili
test
oncolyt
efficaci
sarcoma
erlich
ascit
tumor
mice
none
virus
except
sindbi
viru
knowledg
develop
virotherapi
although
vitro
studi
reveal
phleboviru
famili
bunyavirida
rift
valley
fever
viru
lyse
sever
tumor
cell
type
viru
gain
attent
potenti
virotherapeut
anoth
bunyaviru
bunyamwera
viru
use
human
like
rift
valley
fever
viru
use
cancer
target
sinc
west
nile
viru
famili
flavivirida
use
concurr
treat
patient
advanc
lymphoma
sometim
gave
rise
enceph
larg
dismiss
candid
cancer
therapi
true
flavivirus
ilheu
dengu
well
virus
third
oncolyt
flaviviru
russian
far
east
enceph
viru
never
reach
clinic
due
lethal
enceph
anim
encycloped
sourc
inform
oncolyt
virus
histori
mechan
action
applic
clinic
trial
collect
excel
review
also
found
issu
oncogen
volum
novemb
adenovirus
isol
human
adenoid
tissu
sampl
cultur
undergo
spontan
regress
dub
adenoidalpharyngealconjunctiv
virus
base
capac
induc
diseas
symptom
experiment
infect
human
sinc
adenovirus
becom
wide
use
extens
studi
virus
gene
deliverytherapi
purpos
china
oncolyt
adenoviru
mutant
combin
chemotherapi
accept
standard
treatment
form
refractori
nasopharyng
cancer
immediateearli
gene
express
promptli
upon
adenoviru
entri
cell
two
gene
group
particular
target
modif
order
creat
tumorspecif
virus
normal
product
gene
act
concert
forc
host
cell
enter
phase
prerequisit
rest
viral
replic
process
delet
render
viru
suscept
antivir
mechan
retinoblastoma
rb
protein
specif
block
transit
delet
hand
allow
induc
apoptosi
infect
cell
abort
replic
spread
viru
therefor
product
replic
adenovir
mutant
take
place
cell
defici
rb
glioma
fulfil
requir
thu
becom
ampl
target
select
oncolysi
adenovir
mutant
exampl
adenoviru
vector
frequent
use
experiment
clinic
gene
therapi
howev
specif
mutant
cell
absolut
virus
still
express
protein
overrid
block
impos
infect
cell
eventu
caus
apoptosi
even
normal
cell
also
statu
cell
reliabl
marker
permiss
adenovirus
fact
abil
adenovirus
replic
rather
seem
depend
nuclear
rna
export
machineri
cell
differ
cancer
cell
compar
normal
cell
lack
compens
drug
hyperthermia
enhanc
replic
adenovirus
elev
temperatur
predispos
normal
cell
enhanc
viral
replic
rather
diminish
mutant
shown
superior
oncolyt
efficaci
compar
mutant
vitro
vivo
enhanc
oncolyt
efficaci
mutant
engin
express
function
commerci
vector
advexin
tm
introgen
therapeut
inc
enhanc
late
stage
replic
tumor
cell
induc
apoptosi
facilit
releas
new
virion
strategi
implement
sever
clinic
trial
howev
sinc
primari
tumor
often
express
low
level
primari
adenoviru
receptorth
coxsackieadenoviru
receptor
car
sinc
oncolyt
efficaci
adenovirus
directli
correl
express
level
receptor
adenovirus
may
limit
tumor
target
potenti
therefor
sever
retarget
strategi
develop
exampl
incorpor
tumortarget
peptid
fiber
protein
adenovirus
shown
increas
specif
oncolyt
efficaci
glioma
cell
similarli
placement
rgdmotif
fiber
knob
replic
compet
adenovir
vector
dramat
enhanc
oncolyt
efficaci
human
lung
carcinoma
xenograft
nude
mice
moreov
tremend
potenti
retarget
adenovirus
provid
possibl
replac
nativ
fiber
fiber
human
adenoviru
serotyp
sever
nonhuman
adenovirus
identifi
far
human
adenovir
vector
fiber
protein
canin
ovin
counterpart
show
expand
tropism
vivo
allevi
strict
depend
car
receptor
exchang
fiber
protein
human
adenoviru
type
type
convert
tropism
adenovir
vector
use
often
abund
tumor
cell
compar
normal
cell
extens
review
adenovirus
particularli
retarget
strategi
see
current
employ
adenovirus
clinic
trial
base
human
adenoviru
serotyp
although
employ
differ
mode
tumor
select
sever
adenovir
vector
develop
exampl
although
specif
develop
human
use
canin
adenovir
vector
use
mous
model
cancer
promis
result
vector
base
porcin
bovin
adenovirus
avail
show
effici
transduct
mani
human
cell
line
ovin
adenoviru
type
vector
test
anim
model
cancer
good
result
final
recombin
vector
base
avian
adenoviru
chicken
embryo
lethal
orphan
celo
viru
express
tk
display
combin
relev
prodrug
modest
oncolyt
capac
sever
human
cancer
cell
line
vitro
prolong
anim
surviv
immunocompet
mous
model
melanoma
nonhuman
adenovirus
celo
replic
product
human
cell
therefor
replicationdefici
possibl
util
nonhuman
adenovirus
translat
research
futur
may
appli
clinic
set
human
vector
base
herp
simplex
viru
hsv
togeth
adenovirus
furthest
along
develop
test
virotherapi
date
plethora
hsv
vector
avail
number
preclin
studi
clinic
trial
rapidli
increas
first
replicationcompet
vector
dlsptk
cancer
therapi
malign
glioma
base
f
strain
describ
vector
delet
thymidin
kinas
tk
gene
shown
oncolyt
human
glioma
xenograft
nude
mice
howev
although
tkneg
hsv
vector
attenu
normal
cell
absenc
gene
elimin
possibl
use
commerci
antiherpet
drug
control
infect
therefor
hsv
vector
therapi
use
today
instead
delet
main
neurovirul
gene
sever
restrict
abil
replic
adult
central
nervou
system
cn
form
latenc
inde
deletionmut
first
hsv
vehicl
enter
clinic
trial
howev
order
avoid
gener
wildtyp
wt
hsv
call
secondgener
vector
delet
sever
gene
moreov
becom
clear
delet
gene
also
reduc
replic
effici
modif
restor
effici
introduc
exampl
thirdgener
vector
delet
gene
show
increas
replic
efficaci
oncolysi
anim
model
compar
parent
vector
delet
gene
also
reduc
viral
downregul
mch
class
molecul
thu
enhanc
vector
immunogen
date
five
replicationcompet
vector
enter
clinic
trial
firstgener
vector
recombin
base
strain
delet
gene
ii
formerli
chimer
secondgener
recombin
delet
gene
one
copi
gene
iii
secondgener
vector
delet
gene
ribonucleotid
reductas
copi
gene
iv
oncovex
tm
gmcsf
biovex
wwwbiovexcom
recombin
vector
delet
gene
engin
express
higher
level
compens
reduc
replic
effici
v
vector
multipl
mutat
recombin
hf
strain
vector
proven
safe
phase
ii
studi
ongo
addit
modifi
vector
describ
hsv
variant
full
replic
effici
gener
serial
passag
human
cancer
cell
cell
cultur
also
recombin
hsv
vector
deriv
laboratori
strain
f
less
cytotox
clinic
isol
due
cultur
adapt
respect
recombin
vector
base
clinic
isol
strain
recent
show
enhanc
oncolyt
capac
compar
convent
hsv
vector
due
gene
delet
also
elicit
protect
antitumor
immun
respons
furthermor
oncolyt
capac
mani
hsv
vector
augment
variou
insert
extens
explor
strategi
produc
cytokin
chemokin
eg
gmcsf
vector
stimul
immun
recognit
establish
tumor
immun
anoth
strategi
express
fmg
hsv
vector
even
possibl
screen
recombin
hsv
virus
intrins
membran
fusogen
properti
randomli
mutat
viral
backbon
combin
builtin
abil
express
foreign
fmg
strategi
use
novel
vector
enhanc
oncolyt
capac
even
mani
vector
exist
base
member
herpesvirida
famili
notabl
sinc
also
herp
simplex
type
human
pathogen
interest
viru
result
develop
oncolyt
vector
construct
name
creat
delet
ribonucleotid
reductas
gene
correspond
gene
abrog
tumorigen
potenti
vector
confer
syncytiaform
properti
inde
compar
mention
vector
anoth
oncolyt
vector
base
demonstr
superior
efficaci
even
intraven
iv
administr
nude
mous
model
human
breast
cancer
make
use
natur
tropism
epsteinbarr
viru
ebv
recombin
nononcolyt
vector
base
prototyp
strain
recent
creat
target
bcell
otherwis
notori
difficult
transduc
vector
express
gmcsf
abl
induc
matur
dc
vitro
induc
specif
tcell
activ
thu
consid
vaccin
bcell
lymphoma
furthermor
recent
shown
replicationcompet
bovin
herpesviru
oncolyt
sever
cancer
cell
line
cultur
destroy
human
lung
carcinoma
xenograft
nude
mice
observ
apoptosi
shown
depend
express
viral
gene
addit
convent
hsv
vector
vehicl
base
saimiri
viru
prototyp
subfamili
herp
virus
shown
promis
becom
new
virotherapeut
agent
virus
persist
nonlyt
tcell
engin
express
tk
shown
signific
antitumor
efficaci
anim
model
leukemia
saimiri
viru
also
pseudorabi
viru
genu
varicelloviru
current
develop
cancer
target
tool
oncolyt
cancer
cell
line
strictli
nonlyt
other
nononcolyt
amplicon
vector
base
roseolovirus
human
herpesviru
develop
tumor
vaccin
infect
lymphocyt
macrophag
via
receptor
show
strict
tcell
tropism
similar
vector
base
human
cytomegaloviru
creat
although
oncolyt
capac
cytomegalovirus
unknown
least
murin
cytomegaloviru
display
remark
tumorcontrol
activ
term
apoptot
crisi
activ
function
induc
cell
death
distant
lymphoma
tumor
nest
without
direct
infect
tumor
cell
possibl
use
effect
antitumor
therapi
propos
final
vector
base
equin
herpesviru
recent
construct
yet
test
cancer
target
potenti
taken
togeth
main
advantag
herpesvir
vector
capac
carri
larg
transgen
exceed
kb
set
main
drawback
includ
difficult
clone
even
use
new
bacsystem
safeti
issu
neurotox
high
viru
dose
possibl
oncogen
risk
recombin
activ
endogen
herpesvirus
polyomavirus
doublestrand
dna
virus
rel
small
kb
circular
genom
recombin
polyomaviru
vector
base
viru
around
sinc
turn
millennium
although
inher
nonlyt
cordeli
et
al
recent
demonstr
signific
tumorspecif
vitro
growth
inhibit
mous
model
pancreat
cancer
use
tumorspecif
promot
drive
express
inhibitori
protein
vector
anoth
studi
vector
unabl
transduc
two
human
glioma
cell
line
main
advantag
polyomaviru
vector
remark
abil
escap
immun
recognit
ie
evok
neutral
antibodi
respons
durabl
transgen
express
poxvirus
larg
envelop
dsdna
virus
complex
genom
harbor
multipl
immunemodul
gene
commonli
use
poxviru
cancer
target
vaccinia
viru
vv
wildtyp
strain
wr
caus
local
tissu
destruct
necrosom
deriv
vector
attenu
remov
thymidin
kinas
gene
mani
vv
vector
effici
kill
tumor
preclin
set
exampl
novel
replicationcompet
vector
base
strain
wyeth
show
impress
oncolysi
tumor
metastas
syngen
model
rat
rabbit
upon
iv
administr
howev
although
replicationcompet
vector
abl
enhanc
surviv
immunodefici
immunocompet
mice
carri
differ
type
tumor
signific
infect
organ
also
observ
indic
vv
vector
still
need
optim
given
histori
vv
vaccin
vector
smallpox
common
anticanc
strategi
clinic
trial
tumor
vaccin
transfer
immunoregulatori
gene
besid
viru
prepar
panvac
tm
tricom
tm
also
nononcolyt
fowlpox
viru
avipox
genu
use
trial
cancer
cell
death
respons
vv
occur
apoptosi
mechan
clear
advantag
vector
base
viru
wellestablish
safeti
profil
human
howev
order
avoid
possibl
preexist
host
immun
also
member
poxvirida
famili
consid
cancer
therapi
instanc
yabalik
diseas
viru
ydv
shown
oncolyt
potenti
vitro
vivo
similarli
recombin
vector
base
myxomaviru
previous
thought
infect
rabbit
recent
shown
effici
kill
sever
human
glioma
cell
line
primari
glioma
explant
vitro
markedli
prolong
surviv
mice
two
human
glioma
model
although
virus
replic
vitro
unabl
spread
neighbor
tumor
brain
hemispher
oncolyt
oncotrop
potenti
poxvirus
orf
viru
explor
parvovirus
nonenvelop
singlestrand
dna
virus
kb
genom
famili
includ
helperdepend
virus
dependovirus
includ
adenoassoci
virus
aav
requir
molecular
function
suppli
tran
via
coinfect
herpesor
adenovirus
wherea
autonom
parvovirus
replic
help
cellular
factor
autonom
parvovirus
oncolyt
although
display
oncosuppress
effect
exampl
parvovirus
inhibit
transform
capac
oncogen
virus
shown
suppress
prolifer
cancer
cell
line
induc
cell
cycl
arrest
termin
differenti
nonstructur
protein
parvovirus
caus
epigenet
modif
cancer
cell
revert
benign
phenotyp
thu
antitumor
efficaci
virus
may
involv
oncolysi
tumor
suppress
revers
vector
base
sever
member
dependovirus
use
cancer
target
recent
studi
tumortransduct
efficaci
five
differ
aav
strain
compar
serotyp
prove
effici
killer
solid
tumor
cell
anoth
studi
replicationdefici
vector
base
aav
type
express
antiangiogen
solubl
vegf
receptor
abl
significantli
halt
tumor
progress
sever
rodent
model
glioblastoma
effici
vector
base
serotyp
dupressoir
et
al
demonstr
oncolyt
effect
autonom
rodent
parvoviru
mous
model
mammari
cancer
given
iv
mix
tumor
cell
viru
use
caus
tissu
damag
replic
nontransform
cell
consider
attenu
provid
import
safeti
aspect
similar
result
report
dupont
et
al
use
recombin
minut
viru
mice
viru
infect
panel
cancer
cell
much
effici
normal
cell
recent
wollmann
et
al
demonstr
variabl
permiss
human
glioma
cell
line
two
strain
minut
viru
mice
final
parvoviru
type
unabl
infect
human
cell
use
target
human
cancer
cell
capsid
retarget
exampl
modifi
felin
panleukopenia
viru
current
test
feasibl
cancer
target
tool
reovirus
common
human
respiratori
gastrointestin
tract
seroposit
adult
popul
associ
diseas
attenu
healthi
tissu
reovirus
inher
oncolyt
show
high
tumorspecif
upon
remot
administr
exampl
mark
inhibit
tumor
growth
prolong
surviv
immunocompet
mice
observ
upon
multipl
iv
inject
model
lungmetastas
mammari
cancer
studi
oncolyt
efficaci
reduc
preimmun
anim
indic
preexist
immun
pose
obstacl
viru
combin
treatment
immunosuppress
overcam
restrict
anoth
studi
reoviru
administ
intracrani
ic
abl
erad
breast
cancer
metastas
cn
nude
mice
prolong
surviv
immunocompet
rat
leptomening
breast
cancer
metastas
administ
intrathec
replic
doubl
strand
rna
virus
inhibit
normal
cell
cellular
antivir
defens
machineri
activ
recognit
viral
genom
enzym
pkr
mani
cancer
cell
type
howev
reovirus
abl
replic
unhind
due
inactiv
pkr
oncoprotein
ra
main
advantag
live
reoviru
wellestablish
safeti
profil
man
reoviru
type
dear
strain
current
use
clinic
trial
reolysin
tm
reosyn
tm
wwwoncolyticsbiotechcom
inform
reovirus
cancer
target
see
influenza
virus
use
experiment
cancer
therapi
alreadi
later
oncolys
clinic
trial
howev
influenza
virus
cancer
may
complex
relationship
patient
differ
type
cancer
highli
suscept
infect
influenza
viru
respiratori
virus
particularli
immunosuppress
yet
patient
show
increas
incid
tumor
regress
vaccin
cancer
patient
influenza
report
inhibit
tumor
progress
contrast
vaccin
influenza
shown
provid
protect
certain
type
cancer
later
life
molecular
basi
phenomenon
remain
unclear
protein
influenza
viru
inhibit
activ
pkr
target
cell
turn
permit
viral
replic
pkr
also
inhibit
ra
mani
tumor
cell
type
therebi
constitut
preferenti
target
infect
influenza
viru
recent
studi
bergmann
et
al
report
util
recombin
delet
mutant
influenza
viru
strain
effici
lyse
rasexpress
cell
vitro
subcutan
tumor
model
scid
mice
expect
normal
cell
shown
resist
constitut
import
safeti
aspect
vast
group
virus
includ
prototyp
member
measl
viru
mump
viru
newcastl
diseas
viru
ndv
extens
use
cancer
target
although
still
investig
specif
virus
tumor
cell
like
stem
inabl
tumor
cell
respond
type
interferon
mount
antivir
defens
histori
ndv
antitumor
agent
human
began
clinic
trial
led
dr
cassel
garrett
use
live
attenu
strain
treat
patient
cervic
carcinoma
subsequ
ndv
use
oncolys
live
viru
sever
clinic
trial
exampl
latter
one
studi
purifi
poultri
vaccin
dub
base
live
attenu
ndv
administ
iv
total
patient
grade
iv
glioblastoma
multiform
sinc
patient
five
die
cancer
two
die
caus
remain
seven
aliv
time
publish
paper
four
patient
aliv
year
receiv
iv
viru
sole
form
treatment
anecdot
result
await
confirm
independ
laboratori
use
proper
control
strengthen
supposit
multiresist
brain
tumor
may
treat
peripher
administr
tumorhom
replicationcompet
oncolyt
viru
phase
iii
clinic
trial
use
iv
administr
anoth
live
attenu
neurotrop
ndv
strain
ndvhuj
treat
glioblastoma
three
phase
trial
use
live
ndv
vector
treat
patient
multipl
type
cancer
recent
complet
despit
none
assess
patient
ndvhuj
trial
altogeth
patient
three
trial
durabl
respons
virus
well
toler
less
advers
event
includ
fever
ndvhuj
trial
trial
reaffirm
safeti
ndv
human
moreov
case
tumor
respons
could
likelihood
ascrib
viru
treatment
warrant
continu
develop
virus
virotherapi
ndvhuj
viru
classifi
lentogen
ie
avirul
poultri
capabl
produc
infecti
progeni
tissu
wherea
strain
oncolyt
ndv
strain
consid
mesogen
moder
virul
chicken
year
strain
also
use
human
form
oncolys
target
melanoma
followup
overal
surviv
rate
patient
receiv
immunotherapi
addit
lymph
node
resect
see
chapter
ref
strain
perhap
potent
oncolyt
ndv
strain
studi
date
also
reemerg
experiment
cancer
treatment
studi
addit
number
strain
includ
italien
nononcolyt
lentogen
ulster
strain
use
target
cancer
cell
vitro
vivo
high
specif
report
tumor
vaccin
use
mixtur
nononcolyt
ndv
tumor
cell
may
efficaci
use
oncolys
base
result
numer
anim
experi
clinic
trial
conduct
seem
ndv
extrem
safe
oncolyt
agent
excel
review
oncolyt
strain
newcastl
diseas
viru
see
mump
viru
genu
rubulaviru
also
among
first
paramyxovirus
test
human
asada
report
partial
complet
respons
case
use
urab
strain
treat
patient
differ
malign
later
viru
use
oncolys
treat
varieti
cancer
howev
sinc
live
urab
vaccin
strain
caus
cn
complic
vaccin
individu
attenu
strain
develop
newest
yet
test
cancer
target
one
character
mump
virus
live
attenu
vaccin
strain
show
promis
oncolyt
vehicl
base
select
infect
cancer
cell
vitro
signific
tumor
inhibit
nude
mice
anoth
rubulaviru
simian
viru
engin
cancer
target
although
inher
noncytolyt
viru
shown
kill
sever
cancer
cell
type
cultur
via
product
hsv
tk
follow
treatment
ganciclovir
acyclovir
report
regress
hodgkin
diseas
natur
measl
infect
inspir
measl
viru
use
target
lymphoid
cancer
cell
exploit
natur
tropism
slam
parent
viru
recombin
vector
base
edmonston
b
strain
vaccin
strain
origin
convert
less
pathogen
human
passag
tissu
cultur
abl
inhibit
growth
human
lymphoma
xenograft
scid
mice
either
iv
inject
later
peng
et
al
demonstr
feasibl
use
recombin
measl
vector
preferenti
infect
destroy
human
epitheli
ovarian
cancer
cell
vivo
via
main
receptor
attenu
vaccin
strain
measl
viru
studi
viru
abl
significantli
prolong
surviv
treat
mice
moreov
recombin
vector
base
edmonston
viru
engin
express
carcinoembryon
antigen
caus
mark
regress
ic
glioma
xenograft
nude
mice
vector
enter
phase
clinic
trial
treat
glioblastoma
multiform
recent
oncolyt
efficaci
cultureadapt
moraten
vaccin
strain
live
attenu
jeryl
lynn
strain
mump
viru
compar
edmonston
vaccin
strain
vitro
vivo
result
reveal
replic
kinet
virus
differ
cultur
cell
three
show
similar
oncolyt
efficaci
upon
ip
administr
nude
mice
harbor
human
ovarian
cancer
xenograft
strain
includ
approv
commerci
vaccin
therefor
undergon
comprehens
test
human
certifi
safeti
measl
vector
use
clinic
studi
target
ovarian
cancer
myeloma
cutan
tcell
lymphoma
wwwwileycoukgenmedclin
final
recent
studi
describ
util
vector
base
sendai
viru
genu
respiroviru
infect
kill
sever
differ
cancer
cell
type
vitro
well
erad
human
fibrosarcoma
human
colorect
adenocarcinoma
xenograft
nude
mice
interest
properti
vector
despit
nonproduct
infect
spread
effici
cellfus
mediat
paramyxovirida
fusion
glycoprotein
altogeth
mani
paramyxovirus
display
remark
potenti
anticanc
agent
case
mention
oncolysi
requir
viral
replic
uvinactiv
virus
mediat
cell
death
extens
test
far
rhabdoviru
cancer
target
vesicular
stomat
viru
vsv
genu
vesiculoviru
consider
attenu
human
particularli
sinc
develop
recombin
vsv
vector
two
independ
group
interest
viru
potenti
virotherapeut
explod
recent
studi
shown
iv
administr
replicationcompet
vsv
immunocompet
rat
hepatocellular
carcinoma
significantli
prolong
surviv
ectop
express
fusogen
mutant
f
glycoprotein
newcastl
diseas
viru
enhanc
oncolyt
potenc
extend
anim
surviv
compar
treatment
wt
vsv
anoth
studi
replicationcompet
vsv
engin
express
either
hsv
tk
kill
syngen
breast
carcinoma
melanoma
immunocompet
mice
effici
wt
viru
tumorspecif
vsv
mani
rna
virus
larg
determin
inabl
cancer
cell
mount
effect
antivir
respons
due
defect
type
interferon
signal
pathway
howev
recombin
vsv
still
abl
infect
kill
normal
fibroblast
caus
neurotox
high
dose
may
pose
problem
human
use
therefor
prophylact
treatment
interferon
restrict
spread
vsv
normal
cell
consid
anoth
strategi
mutat
matrix
protein
caus
vsv
elicit
stronger
ifn
respons
restrict
replic
exclus
cell
impair
ifnsign
recombin
vsv
vector
vsv
singl
amino
acid
mutat
protein
recent
use
target
experiment
human
glioma
xenograft
nude
mice
syngen
breast
cancer
metastas
adult
balbc
mice
studi
mutant
viru
well
toler
given
iv
abl
caus
mark
prolong
anim
surviv
model
howev
despit
maximum
toler
dose
mutant
viru
balbc
mice
higher
compar
wt
vsv
vsv
lethal
nude
mice
given
ic
show
mechan
suscept
type
interferon
govern
neurotox
recombin
vsv
similarli
inactiv
paramyxovirus
dead
rhabdoviru
particl
induc
cell
death
excel
review
vsv
oncolyt
agent
provid
ref
coronavirus
obtain
name
appear
electron
microscop
common
respiratori
pathogen
mammal
bird
although
human
coronavirus
await
convers
cancer
target
vector
nonhuman
coronavirus
includ
felin
coronaviru
murin
hepat
coronaviru
display
signific
oncolyt
activ
human
cancer
cell
vitro
tropism
virus
howev
chang
necessari
achiev
infect
nonhuman
coronavirus
normal
infect
human
cell
viral
tropism
thu
determin
sole
basi
express
proper
viral
receptor
cell
surfac
insid
cell
nonhuman
coronavirus
capabl
initi
product
replic
complet
opposit
avipoxvirus
readili
infect
human
cell
multipli
sever
member
posit
strand
rna
virus
develop
tool
virotherapi
polioviru
infect
wide
varieti
human
cancer
cell
line
primari
explant
attenu
neurovirul
polioviru
strain
replac
viral
intern
ribosom
entri
site
ire
correspond
sequenc
close
relat
human
rhinoviru
type
gromeier
et
al
abl
obtain
highli
efficaci
recombin
viru
pv
ripo
display
signific
tumor
tropism
oncolyt
potenti
subcutan
ic
human
astrocytoma
xenograft
nude
mice
wherea
subcutan
tumor
effici
erad
upon
singl
iv
administr
brain
tumor
xenograft
respond
inject
despit
vector
neurotrop
replicationcompet
anoth
studi
viru
abl
caus
complet
tumor
regress
small
number
athym
rat
harbor
ic
human
glioma
xenograft
upon
intrathec
administr
addit
recombin
vector
live
attenu
strain
polioviru
shown
promis
oncolyt
agent
neurotrop
attenu
virus
good
candid
therapi
brain
tumor
inde
ripo
vector
enter
phase
clinic
trial
treat
malign
glioma
coxsackieviru
recogn
antineoplast
agent
test
oncolyt
efficaci
anim
model
today
oncolyt
vector
base
coxsackieviru
avail
phase
studi
target
melanoma
viru
complet
result
yet
publish
anoth
oncolyt
picornaviru
test
bovin
enteroviru
gain
renew
attent
potenti
virotherapeut
viru
show
oncolyt
potenti
toward
varieti
human
cancer
cell
type
includ
lymphoid
origin
moreov
echoviru
type
recent
shown
harbor
strong
tropism
human
ovarian
cancer
cell
studi
tumorfre
surviv
scid
mice
bear
multipl
subcutan
xenograft
observ
week
follow
singl
inject
viru
one
xenograft
final
live
attenu
seneca
valley
viru
genu
unassign
enter
phase
studi
treat
carcinoma
neuroendocrin
origin
neotropix
wwwneotropixcom
first
wave
interest
virus
anticanc
agent
peak
also
member
famili
consid
exampl
attenu
variant
trinidad
donkey
vaccin
strain
venezuelan
equin
enceph
viru
vee
caus
object
tumor
respons
four
patient
moder
aggress
lymphoma
although
recombin
vee
vector
avail
sinc
earli
sever
studi
cancer
vaccin
use
vee
replicon
ongo
report
viru
oncolysi
emerg
sinc
like
mani
rna
virus
alphavirus
highli
sensit
antivir
action
type
interferon
defect
ifnsign
enabl
effect
infect
cancer
cell
tumorspecif
also
enhanc
select
upregul
alphavir
receptor
laminin
cancer
cell
two
prototyp
member
sindbi
viru
semliki
forest
viru
sfv
display
promin
oncolyt
potenti
sindbi
viru
replicon
express
report
protein
shown
kill
sever
cancer
cell
line
vitro
caus
regress
sever
type
tumor
scid
mice
upon
repeat
ip
administr
express
vector
enhanc
antitumor
efficaci
subsequ
studi
immunocompet
mice
vector
abl
reach
dispers
tumor
upon
system
administr
despit
oncolyt
power
replicon
howev
tumor
eventu
regrew
indic
repliconbas
therapi
suffer
limit
transduct
regardless
repeat
inject
respect
live
sindbi
viru
vector
recent
introduc
replicationcompet
vector
base
avirul
strain
shown
suppress
tumor
growth
prolong
surviv
nude
mice
subcutan
metastas
tumor
even
follow
singl
system
inject
anoth
studi
live
sindbi
vector
display
superior
efficaci
specif
sever
virus
vector
base
sfv
show
similar
properti
sindbi
viru
sfv
replicon
effici
first
gener
adenovir
replicon
erad
subcutan
colon
carcinoma
tumor
immunocompet
mice
addit
express
enhanc
version
replicon
significantli
improv
oncolyt
capac
vector
possibl
achiev
oncolysi
preimmun
anim
albeit
lower
efficaci
compar
mice
contrast
studi
smyth
et
al
oncolyt
efficaci
sfv
clearli
enhanc
preimmun
mice
compar
anim
demonstr
alphavirus
may
also
serv
adjuv
treatment
establish
tumor
vivo
similar
studi
sindbi
viru
repeat
administr
sfv
reduc
efficaci
treatment
bring
advers
effect
although
replicationcompet
sfv
prove
efficaci
correspond
replicon
particl
tumor
regrew
treatment
stop
moreov
replicationcompet
viru
studi
base
moder
virul
strain
sfv
thu
less
like
use
human
avirul
strain
experi
show
replicationcompet
vector
base
avirul
strain
sfv
abl
destroy
sever
cancer
cell
line
vitro
well
human
melanoma
xenograft
scid
mice
upon
system
administr
despit
promin
home
tumor
vector
retain
inher
neurotrop
establish
persist
infect
brain
mice
neurotrop
may
serv
asset
target
cn
tumor
notori
difficult
reach
surgeri
member
viru
famili
extens
use
differ
gene
therapi
applic
perhap
frequent
use
retroviru
target
cancer
moloney
murin
leukemia
viru
momlv
due
lack
activ
nuclear
transport
viral
genom
gammaretrovirus
includ
momlv
unabl
transduc
nondivid
cell
consid
import
safeti
aspect
complet
transduct
human
glioma
xenograft
nude
mice
report
follow
singl
ic
administr
replicationcompet
momlv
vector
glioma
appear
site
remot
primari
inocul
spot
also
stain
posit
viral
envelop
suggest
replicationcompet
retroviru
use
transduc
tumor
cn
high
effici
furthermor
viru
detect
nontumor
tissu
demonstr
specif
anoth
studi
replicationcompet
momlv
vector
express
hsv
thymidin
kinas
tk
abl
sensit
syngen
glioblastoma
cell
lewi
rat
ganciclovir
achiev
longterm
day
survivor
notabl
effect
seen
use
replicationdefici
vector
retrovirus
use
clinic
trial
treat
cancer
data
studi
suggest
dissemin
vector
solid
tumor
need
improv
order
reach
clinic
efficaci
besid
gammaretrovirus
vector
base
lentivirus
also
use
target
cancer
preclin
experi
exampl
use
equal
amount
infecti
viru
vsvg
pseudotyp
lentivir
vector
shown
transduc
wide
varieti
tumor
cell
almost
time
effici
vector
base
adenoviru
serotyp
like
retrovir
counterpart
lentivirus
oncolyt
howev
capac
transduc
divid
nondivid
cell
may
advantag
certain
circumst
contrast
gammaretrovirus
lentivirus
spumaviru
foami
viru
show
intrins
oncolyt
capac
recent
studi
replicationcompet
vector
base
prototyp
strain
viru
abl
control
subcutan
tumor
nude
mice
week
although
vector
observ
integr
normal
cell
throughout
bodi
infect
mice
foami
viru
vector
anoth
studi
shown
integr
pattern
differ
retrovirus
appar
prefer
activ
gene
area
may
thu
safer
virus
gene
therapi
applic
despit
promin
increas
cost
anticanc
drug
approv
show
increas
efficaci
provid
cure
cancer
fact
mani
excit
breakthrough
achiev
laboratori
surviv
rate
common
type
cancer
bare
budg
sinc
particularli
treatment
metastat
cancer
convent
modal
chemoand
radiat
therapi
surgeri
fail
due
reason
complementari
altern
medicin
gain
support
virotherapi
assert
potenti
treatment
option
alongsid
convent
therapi
howev
apart
special
case
anecdot
report
success
translat
clinic
virotherapi
also
lack
natur
explan
discrep
result
anim
studi
clinic
differ
host
physiolog
may
sever
confound
assess
safeti
efficaci
virus
human
exampl
pathway
complement
activ
differ
human
mice
anoth
reason
mani
human
virus
replic
well
murin
cell
differ
may
even
exist
rodent
speci
exampl
experiment
data
suggest
vv
vsv
avirul
sfv
replic
better
human
mous
cell
andreanski
et
al
report
glioma
cell
mous
human
origin
permiss
vector
base
glioma
type
cancer
cell
rat
likewis
parvovir
strain
show
strict
hostdepend
exemplifi
rat
parvoviru
replic
mous
cell
make
analysi
tropism
difficult
mous
model
human
cancer
unpublish
observ
corn
et
al
reveal
viru
show
greater
oncolyt
efficaci
human
cancer
cell
prototyp
minut
viru
mous
mvm
murin
counterpart
support
develop
human
cancer
therapi
make
direct
comparison
viral
strain
difficult
base
studi
mous
model
common
misconcept
scid
mice
lack
capabl
respond
virus
fact
despit
sever
immunocompromis
scid
mice
mount
innat
immun
respons
includ
cytokin
complement
macrophag
nk
cell
granulocyt
shown
neutrophil
contribut
significantli
oncolyt
efficaci
recombin
attenu
measl
viru
vector
express
gmcsf
scid
mice
harbor
human
lymphoma
raji
cell
xenograft
also
use
nude
mice
model
human
cancer
although
inform
correl
well
therapeut
efficaci
obtain
man
role
subcutan
xenograft
model
immunodefici
mice
nude
scid
emphas
beyond
indic
valu
measur
safeti
anim
model
may
alway
reliabl
inde
fact
mani
oncolyt
virus
employ
today
elicit
patholog
anim
prevent
reach
clinic
may
surpris
consid
extent
inform
avail
pathogenesi
oncolyt
virus
human
vesicular
stomat
viru
well
known
human
pathogen
caus
extrovert
symptom
man
give
rise
progress
neuropatholog
adult
mice
fatal
outcom
reoviru
type
constitut
similar
contradict
caus
fatal
infect
immunedefici
mice
call
black
foot
syndrom
diseas
man
addit
straindepend
differ
within
viru
famili
may
muddl
assess
pathogen
human
base
studi
singl
member
famili
exampl
wherea
indiana
strain
vsv
lethal
mani
rodent
new
jersey
strain
consider
attenu
least
adult
hamster
vsv
strain
current
use
virotherapi
cancer
attenu
still
carri
sever
point
mutat
enhanc
interferon
respons
toward
virus
render
safe
human
order
solv
problem
interspeci
differ
new
anim
model
develop
instanc
human
polioviru
infect
restrict
cell
express
receptor
rodent
express
receptor
transgen
mous
model
develop
replac
neurovirul
test
cynomolgu
monkey
similarli
transgen
model
develop
assess
pathogen
tropism
measl
viru
normal
infect
mice
true
adenovirus
display
strict
hostdepend
rare
infect
cell
anoth
speci
although
express
earli
gene
cytotox
occur
sever
murin
cancer
cell
shown
permiss
human
adenovirus
facilit
develop
syngen
immunocompet
tumor
model
like
anim
model
alway
function
gateway
clinic
trial
thu
dismiss
instead
improv
upon
util
maxim
degre
recurr
common
outcom
cancer
poor
prognosi
anim
studi
carri
full
extent
arbitrarili
stop
regrowth
like
appear
mani
experiment
studi
crucial
aspect
ignor
despit
would
difficult
follow
treatment
also
metastas
diseas
appear
real
culprit
effort
put
develop
model
dissemin
cancer
alreadi
avail
hope
use
greater
extent
use
properli
anim
model
may
provid
invalu
clue
interact
virus
tumor
live
host
necessarili
predict
final
therapeut
efficaci
case
virotherapi
translat
direct
anim
human
ie
therapeut
anim
therapeut
human
contrast
instanc
drug
develop
multipl
sclerosi
notori
antiifnc
antitnfa
treatment
amelior
anim
model
eae
worsen
human
diseas
nevertheless
efficaci
virotherapi
may
lack
principl
sound
plethora
candid
virus
cancer
therapi
grow
knowledg
safeti
efficaci
variou
host
import
howev
clearli
distinguish
strain
use
draw
broad
conclus
viru
safeti
efficaci
human
base
anim
experi
unaid
common
outcom
virotherapi
escap
tumor
cell
subsequ
regrowth
tumor
chapter
discuss
reason
delin
major
hurdl
virus
face
cancer
therapi
problem
illustr
fig
irrespect
viru
use
whether
replicationcompet
pattern
infect
mani
differ
type
tumor
anim
model
upon
histolog
examin
observ
highli
heterogen
incomplet
even
follow
direct
administr
also
data
grow
number
clinic
studi
suggest
dissemin
virus
tumor
human
glioma
incomplet
contribut
failur
virotherapi
observ
led
research
studi
interact
virus
tumor
tissu
scrutin
fine
morpholog
tumor
mass
highli
variabl
tumor
transduct
observ
sever
tumor
model
system
use
replicationdefici
adenoviru
vector
increas
viru
load
augment
deliveri
transduct
remain
incomplet
plateau
dose
around
viru
particl
transduct
efficaci
invers
proport
tumor
size
small
tumor
transduc
effici
larg
one
studi
grote
et
al
oncolyt
efficaci
live
measl
viru
better
small
cm
tumor
larg
one
also
better
local
deliveri
compar
system
upon
histolog
examin
extract
tumor
nodul
heterogen
viru
dissemin
observ
indic
physic
barrier
viru
spread
similarli
bilbao
et
al
demonstr
limit
access
adenovir
vector
experiment
hepatocellular
carcinoma
nodul
liver
immunocompet
rat
follow
intraarteri
intraport
deliveri
studi
thick
extracellular
matrix
ecm
surround
tumor
nodul
critic
import
restrict
access
viru
capsul
grew
thick
nodul
size
also
progress
increas
compon
basement
membran
substanti
reduc
tumor
permiss
barrier
could
allevi
use
vasoact
compound
histamin
nitroglycerin
reveal
tumor
microvasculatur
larg
respons
access
tumor
howev
despit
increas
access
blood
vasoact
compound
bring
complet
transduct
permiss
highli
depend
tumor
morpholog
indic
intern
barrier
still
remain
yet
anoth
studi
despit
optim
tumor
target
capac
modifi
adenovir
vector
carindepend
tropism
limit
transduct
tumor
metastas
liver
observ
follow
iv
infus
mainli
metastas
tumor
nest
visibl
thinner
extracellular
matrix
endotheli
cell
tumor
cell
compar
untransduc
tumor
foci
studi
extend
li
et
al
demonstr
use
adenovir
vector
immunodefici
mice
carri
liver
metastat
xenograft
number
differ
human
cancer
relationship
transduc
tumor
cell
avail
blood
vessel
adjac
author
show
tumor
cell
close
proxim
bloodvessel
transduc
ecm
inde
pose
signific
barrier
viru
dissemin
studi
mani
other
list
sever
import
conclus
drawn
first
virus
deliv
via
vasculatur
must
cross
blood
vessel
endothelium
layer
matrix
may
separ
endotheli
cell
tumor
research
shown
virus
deliv
iv
much
less
effici
transduc
tumor
nodul
exceed
critic
size
correl
thick
stage
matur
capsul
surround
nodul
threshold
may
differ
depend
type
locat
tumor
affect
degre
ecm
deposit
gener
tumor
size
restrict
factor
macromolecular
drug
deliv
via
circul
second
dissemin
viru
within
tumor
mass
incomplet
singl
inject
given
either
intratumor
remot
locat
wherebi
infect
occur
via
blood
degre
transduct
depend
viru
dose
increas
multipl
dose
vasodil
compound
intern
barrier
within
tumor
mass
may
still
caus
infect
proceed
unevenli
third
hostderiv
connect
tissu
includ
compon
basement
membran
ecm
act
passiv
barrier
viral
spread
kestenbach
elegantli
describ
kinet
xenograft
growth
differ
human
tumor
nude
mice
show
initi
phase
cell
death
mous
fibroblast
rapidli
form
strand
connect
tissu
around
tumor
provid
substrat
format
bloodvessel
turn
sustain
regrow
tumor
tissu
normal
host
cell
includ
fibroblast
almost
without
except
refractori
oncolyt
virus
employ
today
ecm
may
function
decoy
viru
bind
adsorb
viral
particl
thu
prevent
infect
tumor
cell
also
shown
ecm
function
molecular
siev
wherea
movement
larg
particl
nm
diamet
herp
virus
hinder
smaller
nanoparticl
nm
diffus
easili
matrix
addit
physic
barrier
mention
solid
tumor
contain
physiolog
differ
subcompart
may
influenc
viru
entri
diffus
halflif
exampl
area
necrosi
calcif
common
grow
tumor
mass
vivo
prevail
microenviron
character
hypoxia
acidosi
enhanc
proteolyt
activ
may
affect
viru
particl
modifi
cell
surfac
nearbi
live
tumor
cell
unfavor
manner
moreov
elev
interstiti
pressur
solid
tumor
pressur
gradient
within
tumor
may
repel
virus
prevent
enter
spread
tumor
intern
pressur
solid
tumor
nodul
demonstr
increas
constitut
clear
obstacl
deliveri
dissemin
type
macromolecul
final
size
tumor
mass
also
bodili
locat
influenc
home
capac
oncolyt
virus
myer
et
al
recent
demonstr
residu
tumor
mass
mice
bear
human
ovarian
cancer
xenograft
treat
ip
three
differ
oncolyt
virus
two
strain
measl
viru
one
mump
viru
despit
direct
contact
intraperiton
caviti
surviv
tumor
locat
greater
omentum
seemingli
access
inject
virus
anoth
studi
although
replicationcompet
polioviru
abl
find
erad
subcutan
tumor
follow
singl
iv
inject
xenograft
cancer
cell
implant
brain
clear
peripher
administr
requir
ic
viru
inject
affect
mani
solid
tumor
contain
necrot
core
palisad
live
tumor
cell
wherea
activ
prolifer
tumor
cell
found
outermost
viru
antigen
frequent
detect
dispersedli
interfac
necrot
viabl
tumor
cell
see
refer
previou
chapter
typic
pattern
transduct
well
fact
mani
studi
live
viru
live
tumor
cell
found
spur
notion
dynam
equilibrium
infect
die
cell
live
tumor
cell
accord
model
respect
growth
kinet
viru
tumor
cell
determin
outcom
treatment
simplest
scenario
tumor
grow
fast
faster
viru
destroy
therefor
chanc
regrow
viru
clear
immunodefici
mice
dynam
equilibrium
could
maintain
indefinit
wherea
normal
anim
immun
system
probabl
elimin
viru
tilt
equilibrium
favor
tumor
unless
also
tumorimmun
achiev
contribut
unpredict
advanc
oncolysi
call
cell
contact
effect
alter
gene
express
cancer
cell
grow
threedimension
tumor
mass
spheroid
compar
monolay
directli
influenc
tumor
respons
variou
therapeut
moreov
physiolog
distinct
subpopul
cancer
cell
emerg
within
tumor
mass
term
microheterogen
provid
addit
impedi
form
monotherapi
exampl
mani
oncolyt
virus
show
reduc
replic
growtharrest
cell
common
hypox
tumor
region
final
virus
prone
adapt
mutat
model
dynam
equilibrium
inadequ
describ
entir
process
tumor
oncolysi
therefor
elabor
mathemat
model
develop
take
account
confound
aspect
prevail
interact
virus
cancer
although
still
oversimplifi
model
may
prove
valuabl
studi
optim
oncolyt
virotherapi
also
show
addit
growth
kinet
degre
tumor
permiss
influenc
outcom
virotherapi
defin
featur
cancer
cell
abil
evad
death
respond
contactmedi
growthinhibit
apoptot
signal
due
sever
defect
dna
repair
machineri
genom
cancer
cell
highli
malleabl
undergo
sever
mutat
clonal
expans
vivo
passag
vitro
loss
cellular
function
deathinduc
pathway
also
make
cancer
cell
particularli
difficult
erad
inde
common
featur
sever
malign
develop
resist
chemoand
radiat
therapi
term
multiresist
cancer
cell
abil
adapt
almost
challeng
would
concept
develop
resist
virus
differ
studi
recent
observ
emerg
complet
virusresist
melanoma
cell
cours
virotherapi
scid
mice
use
replicationcompet
avirul
sfv
virusresist
cell
probabl
form
due
select
pressur
exert
viru
due
adapt
mutat
tumor
cell
may
elimin
viru
receptor
otherwis
put
cell
nonpermiss
state
consist
concept
microheterogen
could
clearli
show
virusresist
cell
constitut
portion
cancer
cell
isol
residu
tumor
like
contribut
tumor
regrowth
ultim
failur
therapi
sever
research
rais
possibl
virusresist
cancer
cell
despit
promis
tumor
respons
eg
repeat
dose
none
studi
analys
emerg
cell
cours
virotherapi
detail
scrutini
use
histochemistri
explant
cultur
except
one
studi
live
tumor
cell
isol
human
lung
carcinoma
xenograft
day
treatment
oncolyt
bovin
herpesviru
still
suscept
viru
contrast
find
howev
like
virusresist
cell
form
equal
fast
virus
isol
techniqu
play
role
find
cell
therefor
studi
requir
resist
cancer
cell
mani
differ
virus
may
promot
vitro
multipl
round
infect
low
moi
follow
passag
reinfect
surviv
cell
techniqu
employ
gener
tumor
cell
resist
eg
rat
parvoviru
coxsacki
b
viru
minut
viru
mice
encephalomyocard
viru
adenoviru
howev
mani
case
socal
resist
cell
persist
infect
resist
viral
mediat
cell
death
contrast
cell
obtain
studi
resist
also
viru
entri
replic
distinct
import
persist
infect
cell
may
still
suscept
cell
death
via
cytotox
gene
product
encod
viral
vector
recent
alain
et
al
demonstr
use
reoviru
type
persist
infect
raji
cell
deriv
burkitt
lymphoma
could
render
virusfre
treatment
neutral
antibodi
remark
despit
remain
resist
viru
vitro
cure
cell
effici
kill
viru
xenograft
scid
mice
phenomenon
ascrib
vivo
proteolyt
tumor
microenviron
process
virion
form
capabl
infect
resist
cell
studi
alain
et
al
show
virusresist
cancer
cell
gener
vitro
may
still
kill
oncolyt
virus
vivo
contrast
howev
virusresist
melanoma
cell
emerg
vivo
studi
remain
resist
throughout
studi
also
vitro
suggest
cell
distinct
virusresist
cancer
cell
gener
vitro
therefor
assess
presenc
virusresist
cell
tumor
surviv
oncolysi
vivo
may
inform
screen
virusresist
vitro
virusresist
cancer
cell
gener
vitro
parvoviru
found
resist
also
tnfamedi
kill
demonstr
crossprotect
due
overlap
molecular
pathway
resist
find
may
wider
implic
combin
therapi
oncolyt
virus
cytotox
drug
interestingli
upon
gain
resist
viru
parvovirusresist
cell
lose
tumorigen
capac
ie
becom
revert
tumorigen
virusresist
cell
line
acquir
studi
establish
possibl
cell
also
becom
revert
current
unknown
whether
true
virus
whether
tumor
revers
occur
vivo
nevertheless
even
virusresist
cell
lose
tumorigen
may
still
limit
success
virotherapi
pose
passiv
barrier
viru
spread
tilt
dynam
equilibrium
favor
tumor
growth
respect
observ
infect
cancer
cell
oncolyt
herp
virus
induc
apoptosi
neighbor
cell
may
adsorb
bud
virion
prevent
infect
spread
inde
inhibit
apoptosi
cultur
chemic
drug
consider
enhanc
oncolyt
efficaci
vector
thu
inhibit
cell
death
viral
oncolysi
could
fact
enhanc
highli
provoc
idea
may
provid
mean
increas
success
virotherapi
recent
case
report
describ
treatment
boy
anaplast
astrocytoma
grade
iii
live
attenu
newcastl
diseas
viru
reveal
significantli
reduc
viru
replic
one
two
final
stage
third
differ
tumor
mass
resist
mass
shown
histolog
examin
post
mortem
arisen
origin
tumor
thu
despit
therapi
viru
may
show
effici
replic
particular
tumor
mass
patient
may
fail
anoth
type
patient
possibl
reason
strike
phenomenon
discuss
spontan
convers
tumor
cell
virusresist
phenotyp
studi
similar
case
report
studi
treat
glioblastoma
multiform
use
lentogen
ndvhuj
strain
given
iv
tumor
regrew
one
patient
initi
complet
respons
despit
ongo
virotherapi
emerg
phenotyp
indistinguish
genet
differ
subclon
glioblastoma
uncommon
may
underli
observ
increas
resist
viru
ongo
virotherapi
may
addit
exert
select
pressur
provid
growth
advantag
case
seem
tumor
regrowth
dismiss
mere
incomplet
transduct
poor
toxic
underli
reason
may
relat
intrins
resist
therapi
chapter
ref
resist
cancer
cell
variou
form
challeng
extend
also
realm
immunotherapi
instanc
follow
tumor
vaccin
use
influenza
viru
vector
zheng
et
al
observ
tumor
cell
resist
immunemedi
clearanc
due
downregul
taa
agreement
tumor
microheterogen
cell
contact
effect
resist
tumor
occur
mice
heavi
tumor
burden
start
treatment
wherea
anim
smaller
tumor
burden
remain
tumorfre
end
studi
type
tumor
cell
also
observ
escap
recognit
immun
system
ongo
immun
surveil
besid
shed
taa
tumor
cell
may
express
immunosuppress
molecul
ignor
extern
apoptot
signal
fact
cancer
cell
resist
immunemedi
apoptosi
induc
apoptosi
immun
cell
would
potenti
pose
threat
phenomenon
known
tumor
counterattack
hypothet
tumor
acquir
abil
resist
immun
system
extern
onslaught
includ
chemoand
radiat
therapi
oncolyt
virus
practic
becom
impervi
form
treatment
simplic
cell
could
label
omniresist
order
avoid
success
treatment
includ
combin
synergist
therapi
put
even
pressur
precis
scientif
back
plan
treatment
regimen
elucid
common
molecular
target
enabl
facilit
differ
form
treatment
ideal
molecular
mechan
cell
death
viral
infect
tumor
cell
put
context
mechan
prevail
chemotherapi
cytokin
therapi
radiat
therapi
order
reveal
optim
molecular
genet
target
intervent
ultim
provid
tailor
therapi
cancer
cell
defenseless
surprisingli
combin
therapi
nowaday
consid
verit
option
use
adenovirus
monotherapi
employ
virus
may
limit
sever
clinic
trial
conduct
use
common
human
pathogen
consid
innocu
eg
influenza
viru
coxsackieviru
measl
mump
adenoviru
howev
cancer
patient
run
increas
risk
opportunist
infect
coldproduc
virus
sometim
sever
consequ
complic
may
aris
also
virotherapi
virus
potenti
immunogen
may
particularli
high
dose
elicit
unwant
sideeffect
exampl
therapeut
efficaci
dose
particl
adenovirus
administ
iv
elicit
transient
liver
inflamm
lowgrad
dissemin
intravascular
coagul
despit
good
biosafeti
data
accumul
date
problem
unfortun
death
patient
suffer
ornithin
decarbamylas
defici
treat
highdos
adenoviru
serv
grim
remind
peril
involv
use
virus
human
although
harmless
endem
infect
given
directli
blood
virus
bypass
bodi
inher
defens
may
elicit
potenti
fatal
system
respons
anoth
setback
viral
therapi
human
diseas
occur
franc
three
children
sever
xlink
immunodefici
treat
retrovir
transduc
cell
develop
leukemia
relat
viral
integr
activ
oncogen
patient
treat
similarli
trial
recent
begun
show
clonal
domin
immun
cell
repertoir
owe
integr
retrovir
vector
underpin
fact
despit
capac
correct
immunerel
monogenet
disord
integr
vector
come
seriou
risk
need
control
preexist
immun
may
pose
problem
efficaci
virotherapi
discuss
next
chapter
case
may
also
result
exacerb
toxic
exampl
intratumor
treatment
balbc
mice
harbor
subcutan
syngen
breast
cancer
xenograft
adenovir
vector
led
significantli
increas
toxic
preimmun
mice
mortal
compar
mice
mortal
dose
particl
correspond
highest
dose
use
human
preexist
immun
prevent
transduct
peripher
organ
time
increas
liver
toxic
addit
therapi
highdos
viru
may
caus
deplet
cytotox
cell
antivir
interferon
process
known
immun
exhaust
compromis
natur
tumor
immun
reduc
efficaci
tumor
vaccin
render
host
suscept
viral
infect
may
implic
virotherapi
involv
repeat
dose
moreov
undesir
sideeffect
may
emerg
combin
therapi
two
treatment
modal
may
act
synergist
potenti
toxic
exampl
portion
scid
mice
harbor
ip
human
ovarian
cancer
xenograft
die
treat
gemcitabin
retarget
adenoviru
presum
due
liver
bone
marrow
toxic
sensit
normal
cell
either
drug
viru
offer
plausibl
explan
occurr
final
oncolyt
virus
may
equal
suitabl
target
tumor
sensit
locat
brain
rout
administr
may
also
impact
biosafeti
exampl
adenovir
vector
express
hsv
tk
shown
caus
cn
demyelin
mice
upon
ic
inocul
studi
target
leptomening
metastas
rat
nonhuman
primat
administr
adenoviru
express
tk
cerebrospin
fluid
follow
iv
ganciclovir
lead
viral
mening
clinic
trial
recent
abort
intrathec
retrovirustk
therapi
evok
sever
toxic
one
patient
taken
togeth
use
live
virus
human
alway
come
certain
risk
virus
may
immunogen
toxic
other
must
kept
mind
bypass
innat
defens
administr
high
dose
biolog
agent
howev
innocu
may
undesir
consequ
past
year
mani
virotherapi
compani
emerg
unfortun
publish
research
public
forum
put
even
pressur
health
author
control
clinic
trial
mani
virus
develop
virotherapi
burden
daunt
order
facilit
process
provid
imparti
assess
risksbenefit
ratio
fastidi
review
preclin
data
propos
protocol
independ
peer
becom
standard
procedur
major
human
popul
immun
sever
potenti
therapi
virus
preexist
immun
may
pose
problem
howev
virotherapi
virus
seem
benefit
preexist
immun
replic
least
hsv
adenoviru
immun
host
may
limit
delman
et
al
found
contrast
highdos
treatment
pfu
iv
lowdos
pfu
administr
either
fail
reduc
number
tumor
nodul
preimmun
mice
livermetastas
colorect
carcinoma
howev
oncolyt
efficaci
lower
dose
diminish
virus
given
close
proxim
tumor
mass
via
intraport
inject
similarli
mous
model
advanc
periton
gastric
cancer
vector
unabl
halt
tumor
growth
given
iv
instead
ip
thu
even
replicationcompet
hsv
vector
lose
oncolyt
efficaci
administ
site
remot
tumor
high
dose
viru
may
requir
achiev
efficaci
system
virotherapi
moreov
vector
base
murin
leukemia
viru
prone
inactiv
complement
adenovir
vector
often
rapidli
neutral
antibodi
may
despit
retarget
trap
liver
may
caus
signific
toxic
turn
limit
use
system
virotherapi
preexist
immun
may
also
reduc
oncolyt
capac
reovirus
administ
iv
exemplifi
studi
treat
metastat
tumor
studi
immunosuppress
drug
andor
tcell
deplet
significantli
augment
viru
spread
tumor
prolong
surviv
provid
increas
longterm
cure
mechan
viru
inactiv
differ
host
speci
result
obtain
use
laboratori
anim
may
appli
human
problem
prematur
viru
inactiv
probabl
concern
oncolyt
virus
outlin
idea
seem
particularli
promis
overcom
sever
limit
cancer
virotherapi
recent
number
strategi
enhanc
deliveri
drug
solid
tumor
propos
exampl
given
physic
barrier
oncolyt
virus
present
chapter
pretreat
proteolyt
enzym
eg
hyalorunidas
collagenas
could
alter
ecm
thu
facilit
viru
penetr
also
increas
oxygen
tumor
reliev
hypoxia
lower
interstiti
pressur
propos
resensit
tumor
radiat
facilit
drug
deliveri
normal
vasculatur
could
achiev
number
strategi
includ
inhal
hyperox
ga
induct
local
hyperthermia
blockad
vascular
endotheli
growth
factor
signal
vasoact
vasonorm
compound
bevacizumab
bradikynin
lowdos
paclitaxel
leukotrien
also
use
increas
bloodtumor
permeabl
howev
one
studi
even
vasoact
drug
abl
enhanc
adenovir
transduct
solid
tumor
exceed
critic
size
phenomenon
corrobor
later
number
observ
propos
contribut
bloodvessel
permeabl
macromolecular
penetr
becom
dispens
wellestablish
fenestr
tumor
intern
barrier
like
play
major
role
also
efficaci
increas
tumor
permiss
viral
vector
vasoact
compound
may
simultan
increas
risk
tumor
escap
metastasi
discuss
nevertheless
becom
clear
pretreat
tumor
compound
alter
microenviron
benefici
effect
resensit
resist
tumor
reliev
physic
barrier
macromolecular
deliveri
sinc
tumor
transduct
virus
case
incomplet
particularli
tumor
exceed
certain
size
pretreat
enhanc
viru
deliveri
like
becom
critic
step
virotherapi
without
pretreat
foremost
strategi
enhanc
tumor
transduct
virus
use
multipl
administr
exampl
increas
treatment
regimen
two
dose
decreas
variabl
transduct
rate
replicationdefici
adenoviru
vector
repeat
iv
inject
replicationcompet
vsv
vector
significantli
prolong
anim
surviv
compar
singl
viru
dose
syngen
immunocompet
breast
cancer
model
without
increas
toxic
five
consecut
inject
oncolyt
herp
viru
provid
dramat
enhanc
transduct
larg
mm
tumor
xenograft
compar
singl
inject
total
dose
lead
complet
respons
treat
anim
mani
oncolyt
virus
base
common
human
pathogen
preexist
immun
rapidli
clear
virus
thu
multipl
dose
probabl
requir
success
virotherapi
howev
despit
provid
enhanc
efficaci
mani
experiment
set
even
strategi
may
limit
due
intern
barrier
remain
tumor
also
case
intracrani
tumor
repeat
inject
may
feasibl
therefor
strategi
continu
deliveri
via
cathet
convectionenhanc
deliveri
appli
increas
tumor
transduct
within
cn
latter
strategi
use
prospect
phase
iii
studi
treat
glioblastoma
multiform
use
liposom
encapsul
sfv
replicon
addit
pretreat
coinject
tumor
ecmdisrupt
drug
enzym
viral
vector
modifi
express
ecmdegrad
protein
exampl
oncolyt
efficaci
adenovir
vector
engin
express
proteolyt
enzym
relaxin
significantli
enhanc
compar
parent
viru
number
tumor
xenograft
nude
mice
express
relaxin
reduc
intern
collagen
content
tumor
clearli
enhanc
viru
spread
despit
obviou
concern
increas
metastas
potenti
matrixdegrad
environ
treatment
relaxinexpress
vector
fact
reduc
number
lung
metastas
spontan
metastat
tumor
model
compar
parent
vector
member
sever
viru
famili
includ
corona
orthoand
paramyxovirus
capac
induc
cell
fusion
via
fmg
lead
format
multinucl
syncytia
provid
virus
unsurpass
access
build
block
new
virus
possibl
spread
infect
without
extracellular
step
despit
mani
membranefusogen
virus
long
use
target
cancer
notion
use
fusogen
properti
separ
antitumorigen
entiti
conjunct
virus
recent
implement
practic
fmg
alreadi
capabl
kill
cancer
cell
augment
virotherapi
even
facilit
viru
spread
within
tumor
exampl
express
fusogen
mutant
f
glycoprotein
newcastl
diseas
viru
vsv
vector
enhanc
oncolyt
potenc
extend
anim
surviv
compar
wt
viru
likewis
express
hyperfusogen
envelop
glycoprotein
gibbon
ape
leukemia
viru
replicon
vector
base
sindbi
viru
brought
signific
enhanc
therapi
efficaci
ic
glioma
model
nude
mice
syncytia
format
could
circumv
intrins
barrier
present
insid
tumor
includ
high
interstiti
pressur
oncolyt
virus
longer
depend
particl
bud
diffus
infect
neighbor
cell
myriad
modifi
virus
develop
natur
tropism
alter
order
enhanc
specif
tumor
cell
allevi
innat
restrict
tropism
eg
overcom
speciesbarri
addit
viru
retarget
may
function
increas
safeti
reduc
infect
normal
cell
first
replic
dna
virus
express
oncotox
insert
confin
tumor
cell
use
tumorspecif
promot
exampl
progress
elev
promot
human
tyrosinas
promot
relev
enhanc
element
significantli
enhanc
tumorspecif
adenovir
vector
mous
model
human
melanoma
similarli
number
tumor
cellspecif
promot
abl
alter
tropism
replic
compet
retrovir
vector
second
commonli
employ
strategi
achiev
tumorspecif
modifi
exchang
viral
surfac
glycoprotein
respect
adenovirus
undergon
intens
research
multitud
adenovir
vector
alter
tropism
avail
review
retrovirus
effici
retarget
specif
cell
pseudotyp
suitabl
surfac
glycoprotein
vsvg
autonom
parvovirus
retarget
modifi
capsid
protein
also
incorpor
tumorspecif
peptid
sever
differ
gene
deliveri
system
includ
virus
shown
significantli
augment
target
mani
cancer
exampl
tropism
measl
viru
made
strictli
cancer
cell
specif
express
receptorbind
region
singlechain
antibodi
surfac
also
minim
infect
nontumor
cell
express
natur
measl
receptor
slam
howev
peptid
sequenc
incorpor
surfac
glycoprotein
virus
may
also
function
tether
tumorspecif
antibodi
exampl
lentivir
vector
pseudotyp
modifi
glycoprotein
sindbi
viru
capabl
accept
fc
portion
igg
molecul
display
increas
specif
human
melanoma
cell
scid
mice
virus
incub
specif
antibodi
prior
iv
inocul
third
addit
modifi
viral
surfac
mutat
region
viral
genom
increas
specif
oncolyt
efficaci
virus
alter
viral
replic
kinet
cancer
cell
compar
normal
cell
exampl
elimin
gene
vaccinia
viru
strain
wr
significantli
reduc
cytotox
viru
two
human
one
mous
primari
cell
line
simultan
increas
toxic
transform
counterpart
treatment
either
ifna
ifnc
time
fail
abolish
replic
viru
transform
cell
upon
ip
administr
mice
modifi
vaccinia
vector
local
subcutan
tumor
greater
specif
wt
counterpart
vector
titer
peripher
organ
reduc
compar
wt
viru
similarli
delet
tk
gene
vv
strain
wyeth
significantli
diminish
capac
viru
replic
nontransform
nonprolifer
cell
thu
enhanc
tumorspecif
introduct
mutat
restor
replic
effici
convent
delet
hsv
vector
shown
significantli
enhanc
oncotox
without
compromis
viru
attenu
moreov
cancer
cell
often
becom
hypox
target
virus
replic
exclus
cell
emerg
promis
strategi
enhanc
specif
virotherapi
exampl
place
adenovir
gene
control
hypoxiainduc
factor
hif
respons
element
creat
condit
replic
viru
hyprad
show
highli
specif
replic
spread
area
low
oxygen
glioma
xenograft
nude
mice
oncolyt
efficaci
close
replicationcompet
wt
adenoviru
target
hypox
cell
addit
benefit
gener
strategi
may
appli
solid
cancer
thu
less
like
depend
specif
molecular
defect
cancer
cell
may
vari
cell
type
prone
mitig
compens
mechan
overlap
pathway
analog
strategi
make
use
enhanc
proteolyt
microenviron
tumor
strategi
implement
measl
viru
render
apathogen
mice
engin
activ
fusogen
membran
glycoprotein
f
necessari
infect
depend
matrix
metalloproteas
upregul
tumor
rather
furin
oncolyt
efficaci
viru
diminish
mutat
lastli
retarget
virus
coat
tumorspecif
antibodi
addit
option
facilit
least
initi
transduct
cancer
cell
instanc
use
bispecif
antibodi
possibl
target
felin
coronaviru
human
epiderm
growth
factor
express
cancer
cell
howev
case
replicationcompet
virus
antibodi
requir
infect
presenc
subsequ
round
infect
must
ensur
even
within
tumor
thu
strategi
may
difficult
implement
practic
one
possibl
case
vector
express
requir
antibodi
obviou
way
enhanc
cancer
kill
potenc
oncolyt
viru
engin
produc
protein
toxic
cell
either
directli
via
sensit
cell
death
exampl
express
fasligand
trail
adenovir
vector
shown
enhanc
oncolyt
effect
vitro
vivo
without
increas
toxic
normal
cell
addit
directli
cytotox
antineoplast
protein
function
suppress
tumor
growth
exampl
parvoviru
nonstructur
protein
capabl
caus
tumor
revers
also
vpr
nuclear
protein
caus
cell
cycl
arrest
suscept
cancer
cell
type
success
use
experiment
immunocompet
set
erad
cancer
interestingli
antitumor
effect
observ
nude
scid
mice
final
oncotox
insert
protein
use
short
hairpin
rna
express
lentivir
vector
inhibit
survivin
mrna
gave
good
result
nude
mous
model
oral
squamou
cell
carcinoma
oncotox
insert
may
enhanc
robust
virotherapi
particularli
situat
cancer
cell
moder
resist
backbon
viru
evadingactiv
immun
system
virus
recogn
eventu
elimin
immun
system
human
virotherapi
desir
trait
imped
efficaci
treatment
occur
prematur
uncommon
achiev
better
respons
immunocompet
anim
anim
defect
immun
system
also
mean
immunosuppress
allow
enhanc
viral
replic
may
simultan
diminish
antitumor
immun
respons
reduc
efficaci
treatment
even
mani
virus
includ
adeno
herpesand
reoviru
transient
immunosuppress
proven
highli
advantag
exampl
preimmun
igm
present
plasma
rat
human
shown
restrict
transduct
capac
spread
replicationcompet
hsv
vector
administ
intraarteri
treatment
bcell
immunosuppress
agent
cyclophosphamid
abolish
inhibit
allow
effici
transduct
cn
tumor
increas
surviv
time
anim
anoth
studi
treatment
efficaci
reoviru
mice
bear
multipl
metastas
colorect
cancer
dramat
enhanc
pretreat
anim
cyclosporin
order
increas
safeti
immunogen
viral
vector
human
particularli
object
tumor
respons
often
requir
larg
viru
dose
strategi
desensit
immun
system
develop
exampl
prime
innat
immun
system
recombin
ifna
prior
vsv
administr
reduc
replic
significantli
increas
threshold
viru
toxic
immunocompet
rat
strategi
could
potenti
allow
use
higher
viru
dose
human
current
possibl
relat
strategi
administr
lowdos
viru
actual
therapeut
dose
current
implement
number
clinic
trial
minim
viral
elicit
immunedepend
toxic
howev
advers
event
may
occur
despit
appar
toler
repeat
viru
dose
evidenc
sever
system
inflammatori
reaction
develop
patient
fourth
dose
adenoviru
via
hepat
arteri
clinic
trial
treat
livermetastas
gastrointestin
carcinoma
moreov
addit
suppress
desensit
immun
system
virus
made
less
immunogen
one
strategi
mask
virus
polymerco
adenovirus
method
enabl
simultan
enhanc
target
specif
evas
neutral
antibodi
anoth
strategi
involv
encapsul
virus
nonimmunogen
liposom
techniqu
current
employ
phase
ii
studi
target
glioblastoma
multiform
sfv
replicon
also
simpli
choos
appropri
produc
cell
line
halflif
blood
certain
virus
dramat
improv
mlv
complementmedi
inactiv
human
serum
reduc
severalfold
depend
cell
type
use
immunocompet
host
viral
oncolysi
alway
complex
process
involv
immun
system
addit
viru
tumor
viral
oncolysi
tumor
vaccin
overlap
concept
integr
immunestimul
modal
oncolyt
therapi
often
cytokin
chemokin
gain
support
exampl
express
ifnc
condit
replic
adenovir
vector
enhanc
oncolyt
efficaci
compar
backbon
viru
human
xenograft
syngen
mous
model
liver
cancer
importantli
express
ifnc
led
erad
also
larg
cm
xenograft
achiev
parent
viru
encourag
consid
larg
tumor
often
refractori
oncolyt
virus
chapter
anoth
studi
express
human
gmcsf
target
vv
vector
rabbit
metastas
liver
cancer
prove
highli
efficaci
hgmcsf
biolog
activ
rabbit
contrast
mice
express
sfv
replicon
increas
efficaci
vivo
howev
particularli
conjunct
immunemodul
treatment
virus
may
display
unexpect
behavior
viral
replic
depend
immun
respons
last
chapter
briefli
discuss
futur
aspect
oncolyt
virotherapi
data
accumul
far
suggest
oncolyt
capac
virus
although
impress
imped
mani
level
may
requir
assist
order
reach
full
efficaci
combin
strategi
emerg
truli
effect
way
achiev
full
cure
human
fig
also
order
avoid
gener
aforement
omniresist
cancer
cell
tumor
subject
barrag
differ
treatment
form
target
synergist
nonoverlap
molecular
pathway
respect
use
virus
sensit
cancer
cell
form
treatment
vice
versa
proven
highli
promis
instanc
one
report
benefici
effect
virotherapi
fig
two
hypothet
outcom
virotherapi
upper
panel
due
highlight
problem
therapi
ultim
fail
use
viru
infect
alon
sever
strategi
therefor
propos
enhanc
treatment
efficaci
order
achiev
complet
erad
cancer
lower
panel
find
combin
result
optim
treatment
regimen
probabl
becom
increasingli
import
futur
enhanc
combin
radiat
therapi
author
specul
possibl
resist
viru
may
overcom
introduc
multipl
treatment
modal
anoth
studi
adenovir
vector
engin
silenc
cell
cycl
checkpoint
kinas
gene
antisens
rna
shown
sensit
otherwis
resist
cancer
cell
cisplatin
anim
model
liver
cancer
moreov
one
promin
upregul
gene
multiresist
cancer
cell
compar
nonresist
counterpart
gene
ybox
protein
yb
sever
strategi
therefor
develop
target
order
resensit
cell
convent
form
therapi
ie
chemoand
radiat
therapi
one
studi
treatment
prostat
cancer
cell
modifi
condit
replic
adenoviru
led
enhanc
nuclear
local
result
enhanc
viru
replic
increas
sensit
cell
chemotherapi
author
studi
term
notion
use
one
form
therapi
sensit
cancer
cell
anoth
common
molecular
target
mutual
synergist
therapi
anoth
exampl
adenovir
vector
engin
express
dominantneg
nfjb
inhibitor
ijb
render
hela
cell
suscept
tnfa
mediat
apoptosi
vitro
vivo
facilit
releas
virion
spread
viru
final
clinic
trial
squamou
cell
cancer
head
neck
condit
replic
vector
abl
achiev
tumor
respons
wherea
combin
virotherapi
chemotherapi
increas
efficaci
level
patient
least
reduct
tumor
size
patient
clear
cancer
addit
combin
virotherapi
drug
radiat
synergi
also
achiev
use
two
virus
either
conjunct
success
instanc
use
togeth
recombin
hsv
found
enhanc
releas
aav
pancreat
cancer
cell
vitro
vivo
also
sinc
known
echoviru
infect
lead
upregul
cellular
receptor
coxsackieviru
infect
ovarian
cancer
cell
propos
combin
administr
virus
could
lead
enhanc
oncolysi
sever
clinic
trial
use
combin
two
differ
vaccinia
vector
conjunct
chemotherapi
start
moreov
one
viru
use
drive
product
anoth
particularli
larg
dsdna
virus
herp
adenoand
poxvirus
capabl
accommod
larg
insert
includ
virus
instanc
hybrid
hsv
vector
use
drive
product
retrovir
amplicon
target
cell
enabl
significantli
enhanc
tumor
target
transduc
tumor
cell
becom
produc
cell
amplicon
parvovir
replicon
integr
adenovirus
despit
parvovir
protein
initi
prevent
vector
product
hybrid
vector
obtain
produc
cell
express
antisens
rna
furthermor
adenovir
vector
recent
engin
produc
sfv
replicon
via
tissuespecif
promot
natur
tropism
adenovirus
use
target
vector
liver
tumor
rat
tumorcel
specif
ensur
use
afetoprotein
promot
robust
gene
express
cytotox
sfv
exampl
combin
three
strategi
one
system
enhanc
specif
toxic
time
preserv
safeti
extens
review
cover
combin
therapi
strategi
see
despit
grow
number
oncolyt
virus
despit
avid
improv
made
sever
tumor
regrowth
remain
difficult
challeng
virotherapi
one
reason
inadequaci
anim
model
mimic
cancer
human
problem
could
address
use
sophist
model
take
maximum
advantag
one
alreadi
avail
mechan
tumor
surviv
elucid
order
avoid
gener
cancer
cell
resist
convent
treatment
virotherapi
result
preclin
clinic
virotherapi
studi
accumul
becom
increasingli
clear
form
therapi
offer
best
chanc
success
addit
oncolyt
viru
es
optim
treatment
regimen
case
probabl
includ
combin
radiat
chemoor
immunotherapi
howev
appar
effect
combin
two
treatment
modal
one
host
may
introduc
addit
variabl
alreadi
complex
equat
possibl
dire
consequ
one
promin
concern
use
replicationcompet
virus
patient
compromis
immun
eg
radiat
therapi
anoth
difficulti
estim
extent
immun
respons
rapid
oncolysi
particularli
high
viru
dose
therefor
detail
knowledg
immunolog
mechan
greater
understand
molecular
interact
virus
form
treatment
need
